We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

117 hedge funds and large institutions have $938M invested in Coherus Oncology in 2019 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $358K

58% more capital invested

Capital invested by funds: $595M → $938M (+$343M)

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

5% more funds holding

Funds holding: 111 → 117 (+6)

2.69% more ownership

Funds ownership: 96.6% → 99.29% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
117
Holders Change
+6
Holders Change %
+5.41%
% of All Funds
2.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
23
Increased
42
Reduced
31
Closed
17
Calls
$1.18M
Puts
$358K
Net Calls
+$825K
Net Calls Change
+$1.13M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$13.5M
2
PHS
PFM Health Sciences
California
+$12.6M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M
4
TCIM
TIAA CREF Investment Management
New York
+$12.1M
5
Millennium Management
Millennium Management
New York
+$9.96M

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$18.4M
2
CC
Carlson Capital
Texas
-$16.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.04M
4
State Street
State Street
Massachusetts
-$5.57M
5
RCMNY
Rubric Capital Management (New York)
New York
-$5.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$7.49M +$416K +31,205 +6%
PC
27
Pier Capital
Connecticut
$7.17M -$1.09M -81,748 -13%
CC
28
Carlson Capital
Texas
$6.76M -$16.3M -1,224,171 -71%
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$6.74M -$4.4M -329,442 -40%
RPAM
30
Rhenman & Partners Asset Management
Sweden
$6.15M +$1.73M +130,000 +40%
GTC
31
Ghost Tree Capital
New York
$6.14M +$6M +450,000 New
Macquarie Group
32
Macquarie Group
Australia
$5.87M -$4K -300 -0.1%
Invesco
33
Invesco
Georgia
$5.21M +$5.1M +382,299 New
Balyasny Asset Management
34
Balyasny Asset Management
Illinois
$4.81M +$3.49M +261,269 +287%
Charles Schwab
35
Charles Schwab
California
$4.36M +$220K +16,509 +5%
BG
36
Bellevue Group
Switzerland
$4.33M -$558K -41,800 -12%
TCM
37
Tekla Capital Management
Massachusetts
$4.3M – – –
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$4.18M -$959K -71,899 -19%
Mirae Asset Global Investments
39
Mirae Asset Global Investments
South Korea
$4.11M +$144K +10,794 +4%
Wells Fargo
40
Wells Fargo
California
$3.65M -$7.7K -577 -0.2%
SSA
41
Schonfeld Strategic Advisors
New York
$3.5M +$3.42M +256,700 New
SGH
42
Sivik Global Healthcare
Connecticut
$3.07M +$3M +225,000 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$3.06M +$28.8K +2,156 +1%
USAA
44
United Services Automobile Association
Texas
$2.94M – – –
Bank of America
45
Bank of America
North Carolina
$2.94M +$1.19M +88,824 +70%
CWG
46
C WorldWide Group
Denmark
$2.71M +$373K +27,939 +16%
FI
47
Fosun International
China
$2.64M +$1.69M +126,748 +194%
PIM
48
Platinum Investment Management
Australia
$2.6M -$328K -24,586 -11%
TRSOTSOK
49
Teachers Retirement System of the State of Kentucky
Kentucky
$2.58M – – –
ACM
50
Atika Capital Management
New York
$2.56M +$2.51M +188,000 New
1
2
3 4 5

CHRS Hedge Fund Activity: Q1 2019 in Review

117 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2019, worth a combined $938M — up 58% from $595M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CHRS positions and 17 closed out — a net gain of 6 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $13.5M. The largest seller was Deutsche Bank, cutting an estimated $18.4M.

  • 117 institutional investors held Coherus Oncology (CHRS) as of Q1 2019, up from 111 in Q4 2018.
  • Funds reported $938M of Coherus Oncology stock for Q1 2019, up 58% quarter-over-quarter.
  • 23 funds opened new Coherus Oncology positions in Q1 2019 and 17 closed out, a net change of +6 holders.
  • The largest Coherus Oncology buyer in Q1 2019 was JP Morgan Chase, an estimated $13.5M added.
  • The largest Coherus Oncology seller in Q1 2019 was Deutsche Bank, an estimated $18.4M sold.

Based on aggregated 13F filings for Q1 2019.